This activity is expired and is no longer available for CME credit.


Clinical Review of Oral Agents in Late-stage Development for MS Therapy

Author(s)/Faculty: V. W. Yong, PhD
Release Date: 1/13/2017Expiration Date: 1/12/2018
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
Multiple sclerosis (MS) is an inflammatory, autoimmune, degenerative disorder characterized by demyelination and progressive disability. Disease modifying therapies have worked to slow down the rate of disease progression, however, recent studies are currently examining methods to reverse MS-induced neurologic injury and resultant disability through remyelination. This activity focuses on current advances in the area of oral remyelinating agents and its potential to change the MS treatment landscape.